Dr. Karan S. Bhalla, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Years since graduation
- 28
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 727
Licensed in Texas since 2006, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
TX license M3160 (first issued 2006; active) -
Interventional Cardiology Physician
TX license M3160 (first issued 2006; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- University of Texas Medical Branch Galveston Galveston, TX
- Memorial Hermann Houston Physicians Hospital Webster, TX
- St Luke's PAtients Medical Center Pasadena, TX
Medical groups
- Houston Cardiovascular Assoc PA (82 clinicians)
- Karan S Bhalla MD PLLC (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 727
- Services billed
- 11,386
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, regadenoson, 0.1 mg | 1,962 | 505 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,645 | 585 |
| Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | 1,043 | 150 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 837 | 111 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 651 | 491 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 568 | 500 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 546 | 542 |
| Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | 513 | 472 |
| Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan | 474 | 472 |
| Nuclear medicine study of heart muscle blood flow by pet | 372 | 371 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Pasadena, TX | 764 |
| Metoprolol Succinate Other prescribers in Pasadena, TX | 668 |
| Amlodipine Besylate Other prescribers in Pasadena, TX | 654 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Pasadena, TX | 562 |
| Eliquis (apixaban) Other prescribers in Pasadena, TX | 427 |
| Xarelto (rivaroxaban) Other prescribers in Pasadena, TX | 288 |
| Entresto (sacubitril/valsartan) Other prescribers in Pasadena, TX | 251 |
| Metoprolol Tartrate Other prescribers in Pasadena, TX | 214 |
| Furosemide Other prescribers in Pasadena, TX | 198 |
| Olmesartan Medoxomil Other prescribers in Pasadena, TX | 184 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 43 payments worth $6,899 in total to this clinician.
| Boston Scientific Corporation | $6,375 |
|---|---|
| Medtronic, Inc. | $135 |
| Novartis Pharmaceuticals Corporation | $97.42 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $56.33 |
| Pfizer Inc. | $47.19 |
| Heartflow, Inc. | $44.65 |
| Inspire Medical Systems, Inc. | $43.14 |
| Biosense Webster, Inc. | $35.05 |
| Consulting Fee | $5,625 |
|---|---|
| Food and Beverage | $1,274 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_EP | $5,000 |
| Boston Scientific Corporation Oct 23, 2025 | Consulting Fee General - Therapies · General - Therapies_EP | $625 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 6 companies. The companies reported $336,985 in research payments for these studies, mostly to the institutions running them.
- ADVENT Post Approval Study
Boston Scientific Corporation · Active, not recruiting · NCT06431815 - A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)
Amgen Inc. - A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiogra…
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
Boston Scientific Corporation · Active, not recruiting · NCT06096337 - SIMPLAAFY Clinical Trial
Boston Scientific Corporation · Active, not recruiting · NCT06521463 - LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System.
Boston Scientific Corporation · Completed · NCT04790344 - A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome (Explore)
Verona Pharma, Inc. - A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation
Boston Scientific Corporation · Completed · NCT05443594 - Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT)
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.